Goldman Sachs Upgrades Abbvie (ABBV) to Buy amid execution on Humira and growth area
Tweet Send to a Friend
(Updated - December 11, 2023 6:51 AM EST)
Goldman Sachs analyst Chris Shibutani upgraded Abbvie (NYSE: ABBV) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Chris Shibutani upgraded Abbvie (NYSE: ABBV) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
